Fortress Biotech, Inc. $FBIO

What the company doesAI summary of filing

Fortress Biotech is a biopharmaceutical company that acquires and advances biopharmaceutical products and product candidates through subsidiaries and partner companies in order to generate revenue from product sales, equity holdings, and royalties. The company generates revenue from marketed dermatology products sold through its partner company Journey Medical Corporation, including Emrosi, Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Fortress also receives royalty and milestone payments from subsidiaries and partners developing late-stage and early-stage product candidates in oncology, rare diseases, and other therapeutic areas. The company is clinical-stage for most of its product pipeline, with some programs in Phase 1, Phase 2, and Phase 3 development, while certain acquisitions and partnerships provide near-term revenue potential. [10-K 2026-03-31]

Segments: Dermatology (marketed products through Journey Medical), Oncology (CAR T and oncolytic virus programs through Mustang Bio), Rare diseases (Menkes disease, amyloidosis, gout), Other therapeutic areas (CMV vaccine, lysosomal storage diseases)